MTOR and liver cancer: Interestingly, Sorafenib was found to enhance hepcidin gene expression in liver cancer Huh7 cells, together with several other kinase inhibitors, including phosphoinositide 3-kinase (PI3K), mechanistic target of rapamycin (mTOR), Ras/mitogen-activated protein kinase (MAPK), and AMP-activated protein kinase (AMPK) pathway inhibitors (45).